Preoperative ketorolac to prevent recurrence of breast cancer in patients with operable disease

Preoperative ketorolac to prevent recurrence of breast cancer in patients with operable disease

Breast cancer is often diagnosed in its early stages. Surgery, radiation and chemotherapy are standard treatments with curative intent. However, these tumors sometimes recur within the first few years and lead to the majority of breast cancer deaths.

One theory for these early recurrences is that that the body’s response to the tissue injury caused by surgery is to secrete a number of growth factors and cytokines important for tissue repair. Unfortunately, these effects can also cause microclusters of tumor cells lodged in distant locations to start growing and eventually form macroscopic metastases. Thus, a short-term intervention that reduces the peri- operative inflammatory response may reduce recurrence and increase survival.

Anesthesiologists can choose different drugs during surgery, including non-steroidal anti-inflammatory drugs (NSAIDs). A recent study found that in patients undergoing mastectomy for breast cancer receiving a pre-surgical dose of the NSAID ketorolac, the recurrence rate in the first two years dropped from approximately 17% to 6%, a difference maintained over subsequent years. This is a retrospective study. The proposal now is to conduct a randomized prospective trial: operable breast cancer patients will be treated either with or without ketorolac just prior to surgery and recurrences and overall survival will be monitored.

$300,000 - $500,000
If successful, this simple, one-time, affordable, and non-toxic intervention could save 10,000 lives a year annually in the US alone, thereby decreasing mortality in breast cancer by 25%. In healthcare costs, over a billion dollars a year would be saved. A trial in the patients at highest risk of recurrence has begun in Belgium; it would be nice to extend the study to the US. Contact GlobalCures at (781) 269 - 2602 if you would like to Fund this trial.